+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies



Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies



Drug Design Development and Therapy 8: 1235-1247



Amphotericin B (AmB) has been the first-line treatment for visceral leishmaniasis (VL), a neglected protozoan disease, especially in regions like Bihar, India, where resistance to antimonials is widespread. However, adverse drug reactions are a major limiting factor. We evaluated a novel formulation of AmB conjugated to amine-modified graphene (f-Gr) for safety and efficacy over conventional AmB. The f-Gr was prepared in a gentle one-step process of noncovalent (amine) functionalization with the help of amino acid L-cysteine. This f-Gr was further conjugated to AmB by peptide bond. The conjugate (f-Gr-AmB) was characterized by Raman spectroscopy, Fourier transform infrared spectroscopy, scanning electron microscopy, and transmission electron microscopy. f-Gr-AmB was found to exhibit lesser cytotoxicity toward J774A.1 cells than AmB, and did not induce any hepatic or renal toxicity in Swiss albino mice. In vitro antileishmanial assay in J774A.1 cells showed significantly enhanced efficacy of f-Gr-AmB over AmB. Furthermore, percentage inhibition of amastigote replication in a hamster model of VL was significantly higher in the f-Gr-AmB treated group (87.8%) compared to the AmB group (70.4%). These results suggest that f-Gr-AmB could be a safe and effective alternative to conventional AmB in the treatment of VL.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052026045

Download citation: RISBibTeXText

PMID: 25214767


Related references

Surface-Modified Liposomal Formulation of Amphotericin B: In vitro Evaluation of Potential Against Visceral Leishmaniasis. Aaps Pharmscitech 18(3): 710-720, 2017

Characterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: in vitro and in vivo studies. Nanomedicine 7(12): 1839-1849, 2012

Targeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: in vitro and in vivo studies. Nanomedicine 10(7): 1093-1109, 2015

Amphotericin B-loaded nanocarriers for topical treatment of cutaneous leishmaniasis: development, characterization, and in vitro skin permeation studies. Journal of Biomedical Nanotechnology 8(2): 322-329, 2012

Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 93(3): 314-318, 1999

Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B. Journal of the Indian Medical Association 108(1): 27-28, 2010

A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Annals of Tropical Medicine and Parasitology 98(2): 129-138, 2004

Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies. Clinical Microbiology and Infection 24(6): 591-598, 2018

Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Annals of Tropical Medicine and Parasitology 103(8): 727-730, 2009

Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India. Plos Neglected Tropical Diseases 8(1): E2611, 2014

Evaluation of the in vivo leishmanicidal activity of amphotericin B emulgel: An alternative for the treatment of skin leishmaniasis. Experimental Parasitology 164: 49-55, 2016

Visceral leishmaniasis following treatment with liposomal amphotericin B. Clinical Infectious Diseases 19(2): 362, 1994

Liposomal amphotericin B in the treatment of visceral leishmaniasis. Journal of Antimicrobial ChemoTherapy 28 Suppl B: 111-118, 1991

Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clinical Infectious Diseases 43(7): 917-924, 2006

Successful treatment of visceral leishmaniasis with liposomal amphotericin B. Acta Bio-Medica 77(Suppl. 2): 22-25, 2006